Abstract:Chikungunya can have longstanding effects on health and quality of life. Alongside the recent approval of the world's first chikungunya vaccine by the US Food and Drug Administration in November 2023 and with new chikungunya vaccines in the pipeline, it is important to understand the perspectives of stakeholders before vaccine rollout. Our study aim is to identify key programmatic considerations and gaps in Evidence-to-Recommendation criteria for chikungunya vaccine introduction. We used purposive and snowball sampling to identify global, national, and subnational stakeholders from outbreak prone areas, including Latin America, Asia, and Africa. Semi-structured in-depth interviews were conducted and analysed using qualitative descriptive methods. We found that perspectives varied between tiers of stakeholders and geographies. Unknown disease burden, diagnostics, non-specific disease surveillance, undefined target populations for vaccination, and low disease prioritisation were critical challenges identified by stakeholders that need to be addressed to facilitate rolling out a chikungunya vaccine. Future investments should address these challenges to generate useful evidence for decision-making on new chikungunya vaccine introduction. The first vaccine to prevent chikungunya fever has been recently approved in November 2023 by the US FDA and multiple chikungunya vaccine candidates are in different phases of the development pipeline. These will be the first-ever vaccines against an alphavirus and offer new technologies for vaccine development against other viruses of the same family that may cause future epidemics. We interviewed stakeholders from areas at risk of chikungunya outbreaks across Latin America, Asia and Africa, and identified gaps in Evidence-to-Recommendation criteria that should be addressed alongside vaccine introduction. Our findings show that stakeholders from different regions prioritised chikungunya differently, but all stakeholders agreed that the unknown burden of disease, undefined target populations for vaccination and non-specific disease surveillance were challenges that needed to be addressed imminently. To address these gaps, the involvement of stakeholders in all phases of vaccine development and rollout will be crucial to uncover future challenges and to ensure vaccine equity.

Novel chikungunya and dengue vaccines—travel medicine applications

Chikungunya: An Emerging Public Health Concern

Chikungunya virus vaccine: a decade of progress solving epidemiological dilemma, emerging concepts, and immunological interventions

Chikungunya as a paradigm for emerging viral diseases: Evaluating disease impact and hurdles to vaccine development

Current Efforts in the Development of Vaccines for the Prevention of Zika and Chikungunya Virus Infections

Latest developments and future directions in dengue vaccines

Opportunities and challenges of mRNA technologies in development of Dengue Virus Vaccine

THE DENGUE VACCINES: ASSESSMENT OF FUTURE PROSPECTS, TREATMENT, AND VACCINE CHALLENGES

Dengue Fever: Causes, Complications, and Vaccine Strategies

Chikungunya vaccine development, challenges, and pathway toward public health impact

Dengue Vaccines: Current Status and Future Perspectives

Chikungunya vaccines: advances in the development and prospects for marketing approval

The global epidemiology of chikungunya from 1999 to 2020: A systematic literature review to inform the development and introduction of vaccines

Dengue vaccine: an update

Chikungunya infection in returned travellers: results from the geosentinel network, 2005–2020

The relevance of dengue virus genotypes surveillance at country level before vaccine approval

Recent Developments in Recombinant Protein–Based Dengue Vaccines

[The dengue vaccine: a major scientific challenge and a public health issue]

Programmatic considerations and evidence gaps for chikungunya vaccine introduction in countries at risk of chikungunya outbreaks: Stakeholder analysis

The global burden of chikungunya virus and the potential benefit of vaccines

Chikungunya Virus Vaccines: A Review of IXCHIQ and PXVX0317 from Pre-Clinical Evaluation to Licensure